2016
Group Leader
Josep Lloreta Trull
Prostate cancer is the most common noncutaneous cancer in men, and urinary bladder cancer is the fourth most common overall in both sexes. In addition to their prevalence, there are specific features of their respective natural histories that make them two of the cancers that generate some of the highest economic costs and high morbidity rates, and they therefore have a significant impact on patients’ quality of life and on health care costs. These are two different models of carcinogenesis, reflecting diverse aspects of cancer biology. Two major pathways with different molecular, pathological and clinical profiles are well known in bladder cancer. A further advance relies on the identification of several specific molecular subclasses similar to those identified in breast cancer. Also in prostate cancer, the relatively unpredictable behavior of the disease appears to be related to different molecular subfamilies, namely, the complex subset of translocation-associated tumors, and the as yet poorly defined miscellaneous group of tumors not related to gene rearrangements. Furthermore, in both tumors, it has been suggested that inflammatory and immunological responses may be involved in their initiation and progression and these are regarded as new avenues for therapeutic intervention. In both tumors, there is a high demand for markers of early diagnosis, follow-up, and response to therapy, as well as for new therapeutic targets and for parameters that allow a more personalized management of patients. Our objectives are to identify genetic signatures that may be involved in the transition from a hypothetical latent phase to a clinically significant phase, in order to better understand the natural history of bladder and prostatic carcinoma and to design adequate treatment strategies for each patient.
Members
Raquel Albero González (Technician)
Lluís Cecchini Rosell (Researcher)
Albert Francés Comalat (Researcher)
Lluís Fumadó Ciutat (Researcher)
Marta Guix Arnau (Researcher)
Núria Juanpere Rodero (Researcher)
Marta Lorenzo Pérez (Technician)
Gloria Nohales Taurines (Researcher)
more info
Main Publications
• García-Martínez P, López-Aventín D, Segura S, Gómez-Martín I, Lloreta J, Ibáñez J, Elvira JJ, Pujol RM. In vivo reflectance confocal microscopy characterization of silver deposits in localized cutaneous argyria. Br J Dermatol 2016; 175(5): 1052-1055. IF 4.317. Q1
• Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, García-Closas M, et al. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet. 2016;25(6):1203-14. IF 5.985. Q1.
• Hernández S, Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Salido M, Fumadó L, Serrano L, Cecchini L, Serrano S, Lloreta J. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Prostate 2016; 76(9): 854-865. IF 3.778. Q1.
• López de Maturana E, Picornell A, Masson-Lecomte A, Kogevinas M, Márquez M, Carrato A, Tardón A, Lloreta J, García-Closas M, Silverman D, Rothman N, Chanock S, Real FX, Goddard ME, Malats N; SBC/EPICURO Study Investigators. Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models. BMC Cancer. 2016; 16: 351. IF 3.265. Q2.
• Masson-Lecomte A, López de Maturana E, Goddard ME, Picornell A, Rava M, González-Neira A, Márquez M, Carrato A, Tardón A, Lloreta J, García-Closas M, Silverman D, Rothman N, Kogevinas M, Allory Y, Chanock SJ, Real FX, Malats N. Inflammatory-related genetic variants in non-muscle invasive bladder cancer prognosis. A multi-marker Bayesian assessment. Cancer Epidemiol Biomark & Prev 2016; 25(7): 1144-1150. IF 3.622. Q1.
Ongoing Research Projects
• Validación clínica y mecanismos de acción de las alteraciones moleculares con valor predictivo de progresión en el cáncer de próstata: algoritmo molecular de la carcinogénesis prostática
− Fondo de Investigación Sanitaria. ISCIII (PI15/00452)
− From 2016 to 2018
− Principal investigator: Lloreta Trull, Josep
• Validación de nuevas dianas con potencial interés diagnóstico, pronóstico y terapéutico en cáncer de próstata y estudio de sus mecanismos de acción
− Fondo de Investigación Sanitaria. ISCIII (PI12/01426)
− From 2013 to 2016
− Principal investigator: Lloreta Trull, Josep
Group’s Recognitions
• Officially recognised as a consolidated research group by the Generalitat de Catalunya: Grup de Recerca en Càncer Urològic (2014-2017)
− Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 197)
− Principal investigator: Lloreta Trull, Josep
Clinical Trials Signed in 2016
• Estudio observacional, retrospectivo para valorar la eficacia a largo plazo de la quimioterapia de inducción seguida de quimioradioterapia sola en el tratamiento de pacientes con carcinoma escamoso de cabeza y cuello localmente avanzado, no resecable
− Register: TTCC-CIS-2015-01
− Principal investigator: Guix Arnau, Marta
• Estudio de fase IV, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia, seguridad y tolerabilidad de mirabegron en varones con síntomas de vejiga hiperactiva (VH), en tratamiento con el α-bloqueante hidrocloruro de tamsulosina para los síntomas del trato urinario inferior (STUI) debidos a hiperplasia benigna de próstata (HBP). Estudio PLUS
− Register: 178-MA-1008
− Principal investigator: Cecchini Rosell, Lluís
C/ Doctor Aiguader, 88
08003 Barcelona
(+34) 93 316 04 00
info@imim.es